What does ORBITA CTO tell us about CTO PCI?

7 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published May 29, 2026

Coronary chronic total occlusions remain one of the most debated areas in interventional cardiology, with previous large trials showing mixed results on symptom relief and quality of life after CTO PCI.

In this #europcr 2026 interview, John Davies and Sarosh Khan discuss what the ORBITA CTO trial really adds to the field—and why it is drawing so much attention.

As the first double-blind, placebo-controlled randomised trial in CTO PCI, ORBITA CTO was designed to answer a central question: does CTO PCI truly improve symptoms beyond placebo? The discussion highlights the study’s unique design, its key findings on angina relief, and what they mean for everyday clinical decision-making.

What does this mean for CTO operators, and how should general cardiologists interpret these results when managing patients with CTOs?

Hit play to hear the key messages and understand how ORBITA CTO could influence future practice in CTO intervention.

More videos on: https://www.pcronline.com/Cases-resources-images/Resources/Educational-interviews

#cto, #pci, #placebo, #angina, #randomisedtrial, #coronary, #interventionalcardiology